Research programme: Parkinson's disease therapeutics - MicroQuin Therapeutics
Latest Information Update: 03 Sep 2021
At a glance
- Originator MicroQuin
- Class Antiparkinsonians; Neuroprotectants
- Mechanism of Action Bcl-X protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Parkinson's disease
Most Recent Events
- 03 Sep 2021 Preclinical trials in Parkinson's disease in USA (unspecified route)